Drugmaker Eli Lilly plans to buy Verve Therapeutics, a gene-editing startup, for about $1 billion upfront. The deal gives ...

On the sidelines of BIO2025, Julie Gilmore, head of Lilly Gateway Labs, shares her thoughts on the $1.3 billion Verve Therapeutics buy, where Lilly’s therapeutic puck is potentially going and how the ...

According to Adam Parker, founder of Trivariate Research, investors aiming for a defensive approach might want to look at ...

Eli Lilly will buy Boston-based Verve Therapeutics, Inc. in a billion dollar deal with plans to advance Verve's new line of ...

Eli Lilly and Co. is buying Verve Therapeutics Inc. and its gene-editing program for about $1.3 billion. Two of the one-time treatments are in the clinic. Lead candidate VERVE-102, a gene-editing ...

Eli Lilly has agreed to acquire Verve Therapeutics for up to $1.3 billion in a deal designed to bolster the buyer’s cardiovascular treatment pipeline with Verve’s gene editing therapies, led by ...

Eli Lilly agreed to acquire Verve Therapeutics for about $1 billion upfront, adding a potential treatment for cardiovascular ...

Shares of Verve Therapeutics skyrocketed 75% Tuesday morning after Eli Lilly announced that it would acquire the gene-editing ...

Boston-based Verve is a rare example of a gene editing company targeting a disease that affects a large population, offering ...

Eli Lilly and Co. is shelling out $1 billion to buy a Boston biotech known for genetic medicines for cardiovascular disease.

Officials at the FDA say they want to speed up approvals for new drugs and devices using tech like the new "Elsa" AI system. More news is on other uses of AI in health care, Eli Lilly refusing to work ...